Compliance as per Regulation 74(5) of SEBI(Depositories and Participants), Regulations, 2018 for the Quarter ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Oxygenta Pharmaceutical Ltd has filed a routine quarterly compliance certificate under SEBI's Depositories and Participants Regulations for the quarter ended 30 September 2025. The filing confirms that all physical share certificates received for dematerialization during the quarter were duly mutilated, cancelled, and the names of NSDL and CDSL were updated as registered owners within the 15-day SEBI-mandated timeline. The certificate is supported by a confirmation letter from the company's Registrar and Transfer Agent, M/s Venture Capital and Corporate Investments Private Limited, dated 4 October 2025. The submission is a standard procedural requirement and signed by Whole-time Director Balasubba Reddy Mamilla (DIN: 01998852). No corporate action, share movement, or capital change is involved.
No material impact on shareholders or the stock price. This is a routine regulatory housekeeping filing that simply confirms the company's dematerialization process is compliant with SEBI rules.